Bipolar disorders are chronic and recurrent disorders that affect> 1% of the global
population. Bipolar disorders are leading causes of disability in young people as they can …

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

Schizophrenia and bipolar disorder are two distinct diagnoses that share symptomology.
Understanding the genetic factors contributing to the shared and disorder-specific symptoms …

Objective: Pharmacogenomic studies of antipsychotics have typically examined effects of
individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome …

Underrepresentation of Asian genomes has hindered population and medical genetics
research on Asians, leading to population disparities in precision medicine. By whole …

Bipolar disorder (BD) has been associated with immune changes, and yet their underlying
mechanisms are still not fully understood. Here, we review the current state of the field …

Objective: The authors sought to describe the emergent course of bipolar disorder in
offspring of affected parents subgrouped by parental response to lithium prophylaxis …

Bipolar disorder (BD) is a highly heritable mental disorder and is estimated to affect about 50
million people worldwide. Our understanding of the genetic etiology of BD has greatly …

Biological studies of bipolar disorder initially focused on the mechanism of action for
antidepressants and antipsychotic drugs, and the roles of monoamines (eg, serotonin …

Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction.
The application of these scores to pharmacogenomics provides new opportunities to …